146 related articles for article (PubMed ID: 12941031)
1. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty.
Berkowitz SD; Marder VJ; Kosutic G; Baughman RA
J Thromb Haemost; 2003 Sep; 1(9):1914-9. PubMed ID: 12941031
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans.
Baughman RA; Kapoor SC; Agarwal RK; Kisicki J; Catella-Lawson F; FitzGerald GA
Circulation; 1998 Oct; 98(16):1610-5. PubMed ID: 9778325
[TBL] [Abstract][Full Text] [Related]
3. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
4. Orally active heparin and low-molecular-weight heparin.
Pineo GF; Hull RD; Marder VJ
Curr Opin Pulm Med; 2001 Sep; 7(5):344-8. PubMed ID: 11584187
[TBL] [Abstract][Full Text] [Related]
5. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
6. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis.
Gonze MD; Salartash K; Sternbergh WC; Baughman RA; Leone-Bay A; Money SR
Circulation; 2000 Jun; 101(22):2658-61. PubMed ID: 10840020
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
[TBL] [Abstract][Full Text] [Related]
8. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
[TBL] [Abstract][Full Text] [Related]
9. Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
Renda G; Di Pillo R; D'Alleva A; Sciartilli A; Zimarino M; De Candia E; Landolfi R; Di Giammarco G; Calafiore A; De Caterina R
Haematologica; 2007 Mar; 92(3):366-73. PubMed ID: 17339186
[TBL] [Abstract][Full Text] [Related]
10. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR
J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
[TBL] [Abstract][Full Text] [Related]
11. Oral delivery of heparin: SNAC and related formulations.
Pineo G; Hull R; Marder V
Best Pract Res Clin Haematol; 2004 Mar; 17(1):153-60. PubMed ID: 15171964
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Dunn CJ; Goa KL
Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
[TBL] [Abstract][Full Text] [Related]
13. Oral heparin (Emisphere).
Dunn A
IDrugs; 2000 Jul; 3(7):817-24. PubMed ID: 16080057
[TBL] [Abstract][Full Text] [Related]
14. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
15. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty.
Lassen MR; Borris LC; Jensen HP; Poulsen KA; Ejstrud P; Andersen BS
Clin Appl Thromb Hemost; 2000 Jan; 6(1):53-7. PubMed ID: 10726050
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH
J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307
[TBL] [Abstract][Full Text] [Related]
17. Orally administered heparin for preventing deep venous thrombosis.
Gonze MD; Manord JD; Leone-Bay A; Baughman RA; Garrard CL; Sternbergh WC; Money SR
Am J Surg; 1998 Aug; 176(2):176-8. PubMed ID: 9737627
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
[TBL] [Abstract][Full Text] [Related]
19. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
